Fecal Noninvasive Biomarkers Oriented Control Versus Usual Care Strategy in Ulcerative Colitis

NCT07402135 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Noninvasive Biomarkers
Ulcerative Colitis (UC)

Interventions

PROCEDURE: Preemptive therapy escalation based on preset thresholds (FC >250 μg/g or FIT >100 ng/mL) using the FOCUS-UC Ladder:
PROCEDURE: Therapy adjustment only upon clinical relapse (pMS increase ≥2 + rectal bleeding score ≥1).

Sponsor

Qilu Hospital of Shandong University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]